Merck receives marketing authorization for NOBILIS

Merck Animal Health announced that the European Commission has granted marketing authorization for its veterinary medicinal product NOBILIS IB Primo QX to protect chickens against viral infectious bronchitis caused by QX-like variants of infectious bronchitis


NOBILIS IB Primo QX will be the first vaccine developed using SPHEREON technology in the EU, which freeze-dries live vaccines to small, highly soluble particles (spheres) that allow for packaging in light-weight aluminum cups in convenient dose sizes, claims Merck in a media statement.

This vaccine is given to chickens from one day of age or older by spraying onto the chickens or by applying by eye-drop, and provides protection for eight weeks.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email